HTL Biotechnology launches HTL8
A new production unit dedicated to pharmaceutical-grade Polynucleotides (DNA) at our Javené site.
HTL is excited to highlight its participation in IMCAS 2023, a significant event that provided our team with a valuable opportunity to connect with our customers and esteemed partners.
During the event, we had the privilege of sharing insights into our innovative platform and discussing our ambitious future plans. This interaction not only reinforced our relationships but also allowed us to forge new collaborations that will play a role in shaping our company’s journey.
A new production unit dedicated to pharmaceutical-grade Polynucleotides (DNA) at our Javené site.
HTL Biotechnology hosted a scientific summit in Chengdu, China, dedicated to PDRN/PN, bringing together more than 130 experts and professionals to discuss the latest scientific advances, regulatory developments and emerging applications.
Driven by the collective commitment of our teams, this report confirms the maturity of an internationally recognized approach, which was recognized this year with the EcoVadis Platinum medal, placing HTL Biotechnology among the top 1% of the world’s most committed companies.